Details for New Drug Application (NDA): 020219
✉ Email this page to a colleague
The generic ingredient in LIVOSTIN is levocabastine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the levocabastine hydrochloride profile page.
Summary for 020219
Tradename: | LIVOSTIN |
Applicant: | Novartis |
Ingredient: | levocabastine hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION/DROPS;OPHTHALMIC | Strength | EQ 0.05% BASE | ||||
Approval Date: | Nov 10, 1993 | TE: | RLD: | No |
Expired US Patents for NDA 020219
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | LIVOSTIN | levocabastine hydrochloride | SUSPENSION/DROPS;OPHTHALMIC | 020219-001 | Nov 10, 1993 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription